Takwa Wannassi | Plant pathology | Best Researcher Award

Published on by Cell Biologist

Dr. Takwa Wannassi | Plant pathology | Best Researcher Award

Dr. Takwa Wannassi, CRRA Sidi Bouzid, Tunisia

Dr. Takwa Wannassi is a dedicated plant protection specialist and postdoctoral researcher at the Regional Center of Agricultural Research in Sidi Bouzid, Tunisia. With a Ph.D. in Plant Protection and Environment and an Engineering Degree in Horticulture, she brings advanced expertise in entomology, plant-microbe interactions, and sustainable agriculture. Her work is primarily focused on integrated pest management and ecological approaches to crop protection, particularly in Mediterranean agroecosystems. Dr. Wannassi has authored several impactful scientific publications and has contributed significantly to the understanding of invasive pest dynamics, particularly the apricot seed wasp. She plays a crucial role in the international PRIMA project “REVINE,” where she coordinates field trials, mentors students, and collaborates across scientific disciplines. Her dedication to sustainable farming solutions, her extensive research record, and her collaborative spirit make her a strong candidate for the Best Researcher Award.

Publication Profile: 

Google Scholar
Scopus
Orcid

Education:

Dr. Takwa Wannassi holds a Ph.D. in Plant Protection and Environment from Sousse University, Higher Institute of Agronomic Sciences of Chott Mariem (ISA-CM), completed in December 2022. Her doctoral work centered on invasive species and sustainable pest management in Tunisia, particularly the apricot seed wasp Eurytoma samsonowi. She also holds an Engineer Degree in Horticulture with a specialization in Plant Protection, earned in July 2017 from the same institution. Her academic journey reflects a consistent focus on understanding ecological challenges in agriculture and developing innovative, sustainable solutions. Through both degrees, she acquired hands-on skills in molecular biology, field experimentation, pest identification, and biological control. Her academic excellence laid the foundation for her impactful contributions in agricultural research and sustainability science in the Mediterranean region.

Experience:

Since January 2025, Dr. Takwa Wannassi has been serving as a postdoctoral fellow at the Regional Center of Agricultural Research in Sidi Bouzid (CRRA), Tunisia, contributing to the international PRIMA Project “REVINE.” Her responsibilities include coordinating the research project, supervising graduate students, conducting field and lab trials, and analyzing data using R. Her work spans genomic analysis, molecular diagnostics, pest ecology, and microbiome studies. Previously, during her Ph.D., she gained extensive experience in pest ecology, molecular biology, and entomology, particularly in relation to invasive pests such as Eurytoma samsonowi. Dr. Wannassi also collaborates with international institutions, including during a research fellowship in Canada. She is proficient in preparing scientific publications and has presented her findings at major international conferences. Her multidisciplinary approach and leadership in sustainable agriculture research have earned her recognition at both national and international levels.

Awards and Honors:

Dr. Takwa Wannassi has received several accolades in recognition of her contributions to agricultural science and research. In 2019, she earned the Best Poster Award at the Tunisia-Japan Symposium on Science, Society and Technology (TJASSST) for her research on pest behavior and pheromone-based management strategies. That same year, she was granted a Research Fellowship in Canada, allowing her to work at the University of Victoria, British Columbia for two months, enhancing her international research exposure and collaboration. Her continuous efforts in sustainable pest management, microbiome studies, and plant-pathogen interaction have positioned her as a promising researcher in plant protection. She is frequently invited to contribute to scientific conferences and peer-reviewed journals. Her achievements underline her scientific innovation, dedication to eco-agriculture, and her potential as a future leader in Mediterranean agricultural research.

Research Focus:

Dr. Takwa Wannassi’s research centers on plant protection, pest ecology, biological control, and plant-microbiome interactions, with a strong focus on sustainability. Her main scientific interest lies in understanding the behavior and biology of invasive pests like Eurytoma samsonowi, a major threat to apricot production in Tunisia. She utilizes molecular tools, including 16S rRNA sequencing, to explore bacterial communities and Wolbachia infections in pest populations. Additionally, she investigates the role of beneficial rhizobacteria and microbial consortia in disease suppression and grapevine health as part of the PRIMA “REVINE” project. Through multidisciplinary approaches, she integrates entomology, microbiology, and bioinformatics to develop innovative pest management strategies aligned with climate-smart agriculture. Her goal is to promote ecosystem services, biodiversity, and resilience in Mediterranean cropping systems through regenerative and eco-friendly practices.

Publications Top Notes: 

  1. Insights on the bioecology of the invasive apricot seed wasp Eurytoma samsonowi in Tunisia (Biologia, 2023)

  2. Emergence of the apricot seed wasp Eurytoma samsonowi as an economic pest of apricots in Tunisia (Phytoparasitica, 2022)

  3. Prevalence of Wolbachia infection in field populations of the apricot seed wasp (International Microbiology, 2024)

  4. Exploration of bacterial composition and diversity within Eurytoma samsonowi via 16S rRNA sequencing (Symbiosis, 2025)

  5. Harnessing a Microbial Consortium and Compost to Control Grapevine Pathogens (Horticulturae, 2025)

  6. Investigating the potential role of beneficial rhizobacteria for grapevine health and growth (Frontiers in Sustainable Food Systems, 2025)

  7. Biocontrol Assessment of Trichoderma Species on Tomato Crops Infested by Curvularia Spicifera (Frontiers, 2025)

  8. Divergent bacterial abundance and diversity in Eurytoma samsonowi revealed by 16S rRNA (Biochem & Microbiology Congress)

  9. Assessment of damage by Eurytoma samsonowi on apricot fruits in Tunisia (INAT Symposium Poster, 2018)

  10.  Delta traps with virgin females attract Eurytoma samsonowi males: Pheromone control potential (TJASSST, 2019)

Conclusion:

Dr. Takwa Wannassi is an emerging leader in plant protection and agroecology, with a proven record of excellence in research, publishing, and project management. Her work on invasive pest control, microbial consortia, and regenerative viticulture directly addresses critical challenges in Mediterranean and global agriculture. Her multidisciplinary approach, international recognition, and active mentorship highlight her readiness for continued leadership in science. She is highly suitable and deserving of the Best Researcher Award, as she exemplifies innovation, academic rigor, and a commitment to sustainable agricultural development.

Mengting liu | Cell Structure Analysis | Best Researcher Award

Published on by Cell Biologist

Assoc. Prof. Dr. Mengting liu | Cell Structure Analysis | Best Researcher Award

Assoc. Prof. Dr. Mengting liu, Xi’an Jiaotong University, China

Dr. Mengting Liu is an Associate Professor and Master’s Supervisor at the School of Electrical Engineering, Xi’an Jiaotong University. A promising scholar in advanced battery materials, she has made significant contributions to lithium-sulfur, sodium-ion, and zinc-based battery technologies. Dr. Liu holds a Ph.D. in Condensed Matter Physics from Lanzhou University and completed joint doctoral training at the Georgia Institute of Technology, under the mentorship of Prof. Gleb Yushin. As the principal investigator of several high-profile national projects, her work centers around electrolyte design, interfacial chemistry, and cathode material innovation. Dr. Liu has authored over 50 SCI papers in top-tier journals and holds more than 30 patents, reflecting her innovative contributions to electrochemical energy storage. With an H-index of 24 and successful technological transformations, she stands out as a leading young researcher shaping the future of sustainable energy materials in China and globally.

Publication Profile: 

scopus

✅ Strengths for the Award:

  1. High-Impact Publications

    • Over 50 SCI-indexed papers in world-renowned journals such as J. Am. Chem. Soc., Advanced Materials, Energy & Environmental Science, and Nano Energy.

    • Numerous first-author and corresponding-author contributions, showcasing leadership in research.

  2. Innovation in Battery Technology

    • Pioneer in sodium-ion, lithium-sulfur, and zinc-ion battery materials, particularly focusing on interfacial engineering and electrolyte design.

    • Leads cutting-edge research in cold-environment batteries and high-voltage cathodes.

  3. Recognition and Funding

    • Principal Investigator of multiple National Natural Science Foundation of China (NSFC) projects.

    • Successfully translated 3 technologies into industrial application – indicating practical impact.

  4. Patent and Intellectual Property

    • 30+ patents applied/granted, reflecting a commitment to innovation and intellectual property creation.

  5. Academic Metrics

    • H-index: 24, indicating solid citation impact and relevance in the field.

  6. International Exposure

    • Conducted joint Ph.D. research at Georgia Institute of Technology, under the mentorship of global battery expert Prof. Gleb Yushin.

  7. Mentorship and Leadership

    • Serves as Master’s Supervisor, contributing to the training of the next generation of researchers.

🔧 Areas for Improvement:

  1. Public and Global Recognition

    • While the academic output is outstanding, broader international visibility (e.g., keynote speeches, global consortia participation) could strengthen recognition.

  2. Cross-disciplinary Expansion

    • Exploring AI-driven materials discovery or solid-state battery systems could further diversify her portfolio and enhance future relevance.

  3. Team Expansion and Postdoctoral Supervision

    • Expanding mentorship to include postdoctoral researchers and international collaborators could amplify research output and impact.

📚 Education:

Dr. Mengting Liu earned her Ph.D. in Condensed Matter Physics from Lanzhou University (2015–2021), focusing on electrochemical materials and battery interface design. During her doctoral studies, she was awarded a prestigious national scholarship for joint training at the Georgia Institute of Technology (2018–2020), where she conducted cutting-edge research in the School of Materials Science and Engineering under Prof. Gleb Yushin. Her work there focused on advanced cathode materials for sodium-ion and lithium-sulfur batteries, combining material design, characterization, and performance optimization. Her academic foundation is grounded in interdisciplinary training, bridging physics, chemistry, and materials science. Her research was pivotal in understanding phase transitions, solid–electrolyte interfaces, and novel electrolyte systems, which has set the stage for her postdoctoral and faculty research directions in energy storage. Her academic path reflects a strong alignment with innovation in clean energy technologies and fundamental materials science.

🧪 Experience:

Since November 2021, Dr. Mengting Liu has served as an Assistant Professor (Qingxiao Program A) at Xi’an Jiaotong University’s School of Electrical Engineering. She is actively involved in supervising graduate students and leading independent research in electrochemical energy storage. Prior to this role, she spent over two years at the Georgia Institute of Technology during her doctoral studies, collaborating with international experts and engaging in high-impact research. She has led several major research projects funded by the National Natural Science Foundation of China, focusing on electrolyte structure regulation and cathode performance optimization. Her industrial collaborations have led to three technological transformations and over 30 patents. Dr. Liu’s interdisciplinary background and international exposure have enabled her to contribute extensively to frontier research in lithium-ion, lithium-sulfur, and sodium-ion battery technologies. Her teaching and mentoring roles complement her research, contributing to talent development in the energy storage field.

🔬 Research Focus:

Dr. Mengting Liu’s research is centered on electrochemical energy storage, with a particular focus on sodium-ion, lithium-sulfur, and lithium-ion batteries. Her work involves the design of high-performance cathode materials, such as layered oxides and composite structures, and the development of nonflammable, stable electrolytes that enable long-life and high-temperature battery operation. She is especially recognized for her studies on interfacial engineering, including cathode-electrolyte interphases (CEI) and solid electrolyte interphases (SEI), which are critical to battery safety and longevity. Her recent research expands into entropy-regulated materials and polymer electrolytes to tackle extreme environmental conditions like ultra-low temperatures. With a holistic approach combining material synthesis, mechanism analysis, and performance validation, Dr. Liu aims to develop next-generation batteries with high energy density, long cycle life, and environmental adaptability. Her research is not only academically impactful but also industrially relevant, bridging fundamental science with practical innovation.

📄 Publication Top Notes: 

  1. 🧯 Cation−Anion Regulation in Flame-Retardant Electrolytes for Safe Na-Ion Batteries – J. Am. Chem. Soc. (2025)

  2. 🔥 Nonflammable Sulfone-Based Electrolytes for High-Temp LiNi0.5Mn1.5O4 – ACS Energy Lett. (2024)

  3. ❄️ Inorganic-Rich Interphases via Nonflammable Electrolytes for Low-Temp LiNi0.5Mn1.5O4 – Adv. Funct. Mater. (2024)

  4. ⚡ Tailoring Cathode–Electrolyte Interface for High-Power Lithium–Sulfur Batteries – Nano-Micro Lett. (2025)

  5. 🔋 Wadsley–Roth Structure Engineering for High-Power Li-Ion Batteries – Energy Environ. Sci. (2024)

  6. 🔄 Biphaseto-Monophase Transition in Na0.766+xLixNi0.33-xMn0.5Fe0.1Ti0.07O2 – Carbon Energy (2024)

  7. 🛡️ Zn-Ion Channels with Double-Network Layer for Stable Zinc Anodes – Energy Storage Mater. (2024)

  8. 🔗 In-Situ Polymerized Ether Gel Electrolyte for High-Voltage Li-Metal Batteries – Adv. Funct. Mater. (2024)

  9. 🔧 Reinforced Bimetal Oxide-Based PEO Electrolytes for Stable Interfaces – Adv. Funct. Mater. (2025)

  10. ♻️ Phase-Stable and Air-Stable O3-Type Entropy-Reinforced Na Cathodes – Nano Energy (2025)

🧾 Conclusion:

Dr. Mengting Liu is exceptionally well-qualified for the Best Researcher Award. Her track record reflects a rare blend of deep theoretical knowledge, experimental expertise, and real-world application in the fast-evolving field of energy storage.

With a robust publication portfolio, a leadership role in nationally-funded projects, multiple technological transformations, and strong international training, she has already demonstrated leadership and innovation that align perfectly with the purpose of the award.

Zhaowei Feng | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Dr. Zhaowei Feng | Stem Cell Research | Best Researcher Award

Dr. Zhaowei Feng, The Second Affiliated Hospital of Xuzhou Medical University, China

Zhaowei Feng is a dedicated biomedical researcher specializing in neurobiology and pharmacology, currently serving as an Assistant Researcher at The Second Affiliated Hospital of Xuzhou Medical University. With a solid academic foundation and a passion for neuroscience, Feng has made significant contributions to understanding mechanisms of neuroprotection and demyelination. His research spans neurodegenerative disease models such as multiple sclerosis and neonatal hypoxia-ischemia, utilizing molecular and cellular biology tools. Known for his collaborative nature and scientific rigor, Feng has co-authored multiple peer-reviewed articles in prestigious journals and has played pivotal roles in various national and municipal-level research projects. He is particularly recognized for co-first authorship in several studies, reflecting leadership in experimental design and data analysis. His growing influence in the field is further supported by ongoing funded projects and a research trajectory aimed at translational outcomes. Feng is committed to continuing impactful research that bridges bench science with clinical applications.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Strong Research Focus in Neurobiology 🧠
    Zhaowei Feng has a consistent and impactful research portfolio in neurobiology, particularly in myelination, ischemia-reperfusion injury, and glutamate signaling. His work is highly relevant in addressing diseases like multiple sclerosis and neonatal hypoxia-ischemia encephalopathy.

  2. Publications in High-Impact Journals 📚
    He has co-authored several peer-reviewed journal articles in reputable journals such as Phytomedicine, Pharmacology, Oncology Reports, and Frontiers. His contributions as co-first author in multiple papers reflect significant involvement in study design and experimentation.

  3. Independent Researcher Role 🧪
    He currently serves as a Principal Investigator for a municipal-level research project funded by the Xuzhou Health Commission, demonstrating trust in his leadership and research direction.

  4. Multidisciplinary Expertise 🔬
    His research integrates pharmacology, molecular biology, and neuroscience, covering diverse mechanisms like PPARγ signaling, SUMOylation, and ferroptosis, which enhances translational potential.

  5. Rapid Academic Growth 🚀
    Transitioning quickly from a Master’s student (2019–2022) to Assistant Researcher and PI (since 2022) shows a fast-tracked academic trajectory.

⚠️ Areas for Improvement:

  1. Need for More First-Author and Corresponding-Author Papers ✍️
    While co-first authorship is commendable, a stronger emphasis on sole first or corresponding authorship in future publications would establish more scientific independence.

  2. Limited Recognition at National Level 🏅
    Most current funding and achievements are at the municipal level. Applying for national or international grants (e.g., NSFC, NIH) would elevate his research profile.

  3. Postdoctoral Training or Collaboration Abroad 🌍
    Gaining international experience or collaborating with global research centers could broaden perspectives and techniques, increasing citation impact and networking.

  4. More Diversified Research Outputs 📊
    Exploring patents, clinical trials, or translational research outcomes could further demonstrate innovation and application potential.

🎓 Education:

Zhaowei Feng began his academic journey in the biological sciences at Xuzhou Medical University, where he earned his Bachelor’s degree between 2014 and 2018. He further pursued a Master’s degree in Neurobiology at the same institution from September 2019 to July 2022. His graduate studies were marked by an intensive focus on neurodegenerative mechanisms, including demyelination and neuroinflammation, with particular attention to cuprizone-induced and ischemia-reperfusion mouse models. His research also explored glutamate transport regulation, the PPARγ pathway, and oligodendrocyte differentiation. His educational foundation not only provided him with technical proficiency in experimental neuroscience but also cultivated a strong understanding of translational biomedical research. Through rigorous coursework, laboratory experience, and thesis writing, Feng developed a robust academic profile that seamlessly transitioned into his research career. His educational journey reflects consistent dedication and a clear trajectory towards clinical and experimental neurobiology.

🧪 Experience:

Since September 2022, Zhaowei Feng has been working as an Assistant Researcher at The Second Affiliated Hospital of Xuzhou Medical University. His role involves leading preclinical studies, managing collaborative projects, and mentoring junior researchers. Feng has also served as Principal Investigator on a municipal-level research grant focusing on blood-brain barrier damage post-transplantation. He actively participates in multiple interdisciplinary studies involving neurodevelopment, myelination, and pharmacological interventions. Prior to his current role, his Master’s research provided hands-on experience with animal models, molecular techniques, and data analysis in neurobiology. Feng has authored or co-authored numerous research papers, some as co-first author, contributing significantly to study design and execution. He is also involved in translational research projects that aim to bridge laboratory findings with clinical therapies. His work ethic, attention to detail, and innovative approach make him a valuable contributor to the field of neurobiological research.

🏅 Awards and Honors:

Zhaowei Feng has been recognized for his scientific contributions through both academic and research-oriented accolades. Notably, he is the recipient of a research grant from the Xuzhou Municipal Health Commission (Project No. XWKYHT20230029), focusing on cerebral ischemia-reperfusion and blood-brain barrier injury. Though early in his professional career, his selection as Principal Investigator on this project signifies trust in his leadership and expertise. Several of his publications in high-impact journals list him as co-first author—an honor that highlights his equal contribution in rigorous experimental work. While he has yet to receive national awards such as from the Natural Science Foundation, his steady academic output and funded research projects mark a strong trajectory. His growing publication record and role in significant studies position him as a rising talent in the biomedical field. Future honors are likely as his research continues to address key questions in neuroscience and pharmacology.

🔬 Research Focus:

Zhaowei Feng’s research centers on neuroprotection, demyelination, and neuroinflammation, with a particular focus on the mechanisms underlying multiple sclerosis, ischemic brain injury, and neonatal encephalopathy. His studies often employ animal models such as cuprizone-induced demyelination and hypoxia-ischemia to explore therapeutic targets. Feng is particularly interested in the regulation of oligodendrocyte differentiation and the role of glutamate transporters, signaling molecules like PPARγ, and pathways involving Wnt/β-catenin and SUMOylation. Additionally, he has investigated compounds such as diosgenin and alpha-asaronol for their neuroprotective and remyelination-promoting effects. His work also extends into cancer biology, with studies on ferroptosis and protein regulation in squamous cell carcinoma. By integrating molecular biology, pharmacology, and neurodevelopmental research, Feng aims to contribute to the discovery of new treatments for central nervous system disorders. His current and future research is geared toward translational medicine that bridges laboratory science with clinical applications.

📚 Publication Top Notes:

  1. 🧠 Alpha-Asaronol Alleviates Dysmyelination by Enhancing Glutamate Transport via PPARγ-GLT-1 Signaling in Neonatal Hypoxia-Ischemia (Pharmacology, 2022)

  2. 🧬 C1q Inhibits Differentiation of Oligodendrocyte Progenitor Cells via Wnt/β-Catenin Signaling (Biomedicine & Pharmacotherapy, 2023)

  3. 🧪 Alpha-Asaronol Promoted OPC Differentiation and Improved Myelination as a PPARγ Activator (Frontiers, 2023)

  4. 🧫 Diosgenin Promoted OPC Differentiation by Blocking GLUR2/GAPDH Interaction in Pilocarpine-Induced Epilepsy Rats (Phytomedicine, 2025)

  5. 🧬 Netrin-4 Mediates Piezo1 Inactivation and YAP Signaling Alleviation in Cerebral Ischemia-Reperfusion (Oncology Reports)

  6. 🔬 SENP1 Inhibits Ferroptosis and Promotes Head and Neck Squamous Cell Carcinoma by Regulating ACSL4 Protein (Molecular Oncology, 2023)

  7. 🧪 SUMO1-Mediated Stabilization Enhances Protein Function in Neuroinflammatory Models (Unspecified Journal)

  8. 🧠 Signaling Activation in a Cuprizone-Induced Mouse Model of Multiple Sclerosis (Unspecified Journal)

📌 Conclusion:

Zhaowei Feng is a highly promising early-career researcher with a clear scientific focus, a growing publication record, and demonstrated ability to lead independent research. His work addresses critical challenges in neurobiology and pharmacology, making a tangible impact in both experimental and translational medicine. With continued progression—especially toward national-level recognition and senior authorship—he has the potential to become a leader in his field.

Nabil Alshurafa | Molecular Mechanisms Signaling | Best Researcher Award

Published on by Cell Biologist

Prof. Nabil Alshurafa | Molecular Mechanisms Signaling | Best Researcher Award

Prof. Nabil Alshurafa, Northwestern University, United States

Dr. Nabil Alshurafa is a tenured Associate Professor at Northwestern University’s Feinberg School of Medicine in the Department of Preventive Medicine. A recognized expert in wearable health technology and artificial intelligence, his work bridges computer science and preventive health. With a strong foundation in AI, embedded systems, and wireless health, Dr. Alshurafa is known for pioneering research that transforms how chronic conditions are monitored remotely. He has held prestigious fellowships, serves on influential editorial boards, and contributes actively to global conferences. Passionate about advancing digital health, his interdisciplinary approach fosters innovation in non-invasive health monitoring technologies. His body of work, including over 100 peer-reviewed publications and several with high citation metrics, has significantly shaped mobile and wearable health sensing technologies. Known for collaborative leadership and visionary research, he continues to inspire advancements in AI-driven healthcare.

Publication Profile: 

Google Scholar

✅ Strengths for the Award:

  1. Innovative Research Focus:
    Dr. Alshurafa is a pioneer in AI-powered wearable health technologies, focusing on practical, non-invasive solutions for chronic disease management, nutrition monitoring, and human activity recognition.

  2. High-Impact Publications:
    His publications are well-cited, including several landmark works like “Deep learning in human activity recognition…” and “NeckSense…” that demonstrate translational value in digital health and mobile sensing.

  3. Prestigious Roles & Affiliations:
    Editorial roles with ACM IMWUT, IEEE, and Nature Digital Medicine, along with organizational roles in IEEE PerCom, underscore his peer recognition and leadership in the field.

  4. Award-Winning Work:
    His research has received Best Paper Awards and has been presented at highly selective conferences with acceptance rates as low as 10–25%.

  5. Interdisciplinary Impact:
    His work intersects computer science, biomedical engineering, and preventive medicine, which is critical in tackling modern healthcare challenges through integrated technology.

  6. Real-World Applications:
    Tools like WANDA, NeckSense, and smart bedsheets reflect direct applicability to patient care and wellness monitoring.

🔧 Areas for Improvement:

  1. Global Visibility:
    While his national recognition is strong, increasing presence in international healthcare policy and standards bodies could elevate his global influence.

  2. Cross-Sector Translation:
    Although academically impactful, more visible industry collaborations or commercial deployments (e.g., FDA-approved products or spin-offs) would enhance the translational credibility of his work.

  3. Public Engagement:
    Expanding outreach through public talks, tech-for-health summits, or popular science channels would help bring his innovations closer to everyday users and clinicians.

  4. Broader Health Diversity Applications:
    More research could be targeted toward underserved populations or global health settings, showcasing scalability and equity of the solutions.

🎓 Education:

Dr. Nabil Alshurafa began his academic journey at the University of California, Los Angeles (UCLA), earning a Bachelor of Science in Computer Science in 2003 with summa cum laude honors. He further pursued graduate education at UCLA, receiving his Master of Science in Computer Science in 2010 with a specialization in Artificial Intelligence. His graduate work laid the foundation for his future contributions in AI-powered healthcare. To gain applied research experience, he joined UCLA’s Wireless Health Institute from 2013 to 2015 as a Wireless Health Fellow. This multidisciplinary training equipped him with expertise in sensor technology, machine learning, and biomedical systems. The academic rigor and technological immersion at UCLA played a pivotal role in shaping his research direction—particularly in remote health monitoring and ubiquitous computing, which have become the hallmarks of his career.

🧪 Experience:

Dr. Alshurafa’s career spans academia, research, and editorial leadership. Since 2022, he has served as a tenured Associate Professor at Northwestern University, where he leads innovative projects in wearable computing and health analytics. His prior fellowship at UCLA’s Wireless Health Institute (2013–2015) was instrumental in honing his applied skills in biomedical sensing and embedded AI systems. He has contributed to multiple high-impact research studies, demonstrating leadership in both collaborative and solo research environments. Beyond teaching and mentoring, Dr. Alshurafa plays a key role in global health informatics networks, serving on editorial boards such as ACM IMWUT, PLOS ONE, and Nature Digital Medicine. His industry engagement is evident from his organizational roles at IEEE PerCom, where he has served as Industry Track Chair and Sponsorship Chair. These roles reflect his commitment to bridging academia with real-world technological solutions in preventive and mobile health.

🏅 Awards and Honors:

Dr. Alshurafa has been recognized for his academic excellence and leadership in health informatics. He is a member of ACM and has held key editorial positions in ACM Interactive, Mobile, Wearable, and Ubiquitous Computing (IMWUT). His roles with IEEE PerCom as Industry Track Chair (2018) and Sponsorship Chair (2019) highlight his prominence in mobile health computing communities. His research has been distinguished with honors such as Best Paper Award at the IEEE International Conference on Wearable and Implantable Body Sensor Networks (BSN). Additionally, several of his publications have been widely cited, underscoring his influence in the field. His editorial board memberships across journals like PLOS ONE, IEEE Biomedical Health Informatics, and Nature Digital Medicine showcase peer recognition of his expertise. Collectively, these accolades reflect a sustained and impactful contribution to health technologies and interdisciplinary research.

🔬 Research Focus:

Dr. Nabil Alshurafa’s research centers on AI-driven wearable technologies for remote health monitoring and behavioral health sensing. He focuses on building unobtrusive, sensor-based systems that can track physiological signals and behaviors such as eating, physical activity, and sleep in real-world environments. By integrating machine learning with low-power embedded systems, he develops scalable tools for chronic disease management, including heart failure and diabetes. His work leverages signal processing, stochastic modeling, and deep learning to transform raw sensor data into clinically actionable insights. A key contribution is his development of NeckSense, a multi-sensor necklace for detecting eating behaviors, and WANDA, an end-to-end health monitoring system. Through interdisciplinary collaborations, he also explores nutrition sensing, exergaming, and rehabilitation technologies. His ultimate goal is to enable proactive, personalized healthcare solutions that reduce the burden on patients and providers alike while enhancing wellness through smart, wearable ecosystems.

📚 Publications Top Notes: 

  1. 🕷️ Artificial Spider: Eight-legged arachnid and autonomous learning of locomotion

  2. ❤️ WANDA: An end-to-end remote health monitoring and analytics system for heart failure patients

  3. 🔋 Opportunistic hierarchical classification for power optimization in wearable movement monitoring systems

  4. 🩺 Dynamic task optimization in remote diabetes monitoring systems

  5. 😴 Inconspicuous on-bed respiratory rate monitoring

  6. 🛏️ A dense pressure sensitive bedsheet design for unobtrusive sleep posture monitoring

  7. 👕 Improving accuracy in E-Textiles as a platform for pervasive sensing

  8. 🚶 Robust human intensity-varying activity recognition using Stochastic Approximation in wearable sensors

  9. 🏋️ On-bed monitoring for range of motion exercises with a pressure sensitive bedsheet

  10. 🎮 MET calculations from on-body accelerometers for exergaming movements

🧾 Conclusion:

Dr. Nabil Alshurafa stands out as an exceptionally qualified candidate for the Best Researcher Award. His work embodies the intersection of innovation, application, and societal benefit. He has demonstrated leadership in both research productivity and community contribution, with a track record that is not only prolific but also highly relevant to the future of preventive and digital healthcare. His pioneering systems in wearable health monitoring have the potential to transform how health is tracked and managed in real time, offering personalized insights and clinical utility.

Xiaozhi Liu | Cell-Cell Communication | Best Researcher Award

Published on by Cell Biologist

Prof. Xiaozhi Liu | Cell-Cell Communication | Best Researcher Award

Prof. Xiaozhi Liu, Tianjin Fifth Central Hospital, China

Dr. Xiaozhi Liu, born on December 10, 1979, is a distinguished medical researcher and Director of the Central Laboratory at Tianjin Fifth Central Hospital. With over two decades of experience in neurosurgery and translational research, he has made substantial contributions in neural regeneration and SUMOylation-related mechanisms. Dr. Liu is a prolific academic with numerous publications in top-tier journals and active involvement in multiple National Natural Science Foundation of China projects. His international exposure as a visiting scholar at Duke University Medical Center (2012–2013) enhanced his global scientific perspective. Dedicated to neuroscience innovation, he combines advanced molecular biology techniques with clinical applications to improve patient outcomes in neurological disorders. Recognized for his scientific rigor, leadership, and innovative research approach, Dr. Liu is an exceptional candidate for the Best Researcher Award.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. Innovative Research Focus: Dr. Liu’s expertise in SUMOylation, neural regeneration, and gene regulation presents a cutting-edge approach to treating cerebral ischemia, glioblastoma, and cardiac injury.

  2. Strong Grant History: He has led multiple prestigious National Natural Science Foundation of China (NSFC) projects as both PI and co-investigator, with substantial funding and scientific merit.

  3. Impressive Publication Record: Over 15 peer-reviewed publications in impactful journals (Stroke, Aging, Neuroscience, etc.), with topics ranging from brain ischemia to cardiac injury, illustrate interdisciplinary strength.

  4. Leadership Role: As Director of the Central Laboratory, he demonstrates strong research management, mentoring, and institutional collaboration capabilities.

  5. Global Perspective: His time as a visiting scholar at Duke University Medical Center enhanced his academic and cross-cultural research competencies.

  6. Clinical & Basic Science Integration: Combines bench-to-bedside applications, especially in neurosurgery and molecular biology.

⚠️ Areas for Improvement:

  1. International Outreach: While academically robust in China, Dr. Liu could benefit from increased global collaboration, co-authorship with foreign institutes, or keynote speaking roles at international conferences.

  2. Patent & Innovation Translation: There’s potential to strengthen the translational commercialization of his research findings through patents or biotech partnerships.

  3. Public Engagement: Increasing public science communication and media presence could enhance his visibility in broader scientific and policy-making communities.

🎓 Education Background:

Dr. Xiaozhi Liu began his academic journey at Zhangjiakou Medical College, completing a degree in Clinical Medicine in 2003. He pursued his passion for neurosurgery at Tianjin Medical University, where he earned a master’s degree in 2007 and later a Ph.D. in 2017. His academic pursuit extended internationally with a one-year research fellowship at the Duke University Medical Center in the United States (2012–2013), where he specialized in neurosurgical studies. Throughout his academic training, Dr. Liu has demonstrated a deep commitment to the integration of clinical knowledge with cutting-edge biomedical research, particularly in the areas of neuroregeneration and molecular neuroscience. His academic background laid a strong foundation for his contributions to neurobiology, clinical translation, and innovative research in SUMOylation, gene expression regulation, and therapeutic interventions for neurological diseases.

🏥 Work Experience:

Dr. Liu began his clinical career as a Neurosurgery Resident at the Affiliated Hospital of the Chinese People’s Armed Police Force Medical College from 2007 to 2009. He then served as a physician in the Department of Neurosurgery at Tianjin Fifth Central Hospital until 2012. Since December 2013, he has been serving as the Director of the Central Laboratory at the same institution. In this role, he has spearheaded major research initiatives and supervised clinical translational projects in neurobiology. His leadership has been instrumental in establishing a multidisciplinary research environment that bridges clinical neuroscience and molecular biology. His extensive experience in both hospital-based patient care and laboratory-based scientific discovery places him at the intersection of clinical excellence and research innovation. His career trajectory reflects an unwavering commitment to advancing medical science and improving patient care.

🔬 Research Focus:

Dr. Xiaozhi Liu’s research centers on the molecular mechanisms of neuroregeneration, focusing particularly on SUMOylation, gene expression modulation, and neural stem cell therapy. His work explores the protective roles of SUMO-modified proteins in ischemic stroke, glioblastoma suppression, and spinal cord injury recovery. Dr. Liu investigates the role of small RNAs, mitochondrial dynamics, and oxidative stress in neurodegenerative conditions and cardiovascular diseases. His approach combines genomic, proteomic, and cell-based assays to understand the therapeutic potential of modulating cellular stress responses. Ongoing collaborations on stem cell transplantation, chromatin remodeling in cardiac diseases, and translational neuroscience further exemplify his dedication to interdisciplinary science. With an extensive list of national research grants and peer-reviewed publications, Dr. Liu remains at the forefront of biomedical innovations aimed at reversing tissue damage and enhancing neuroplasticity.

📚 Publication Top Notes:

  1. 🧠 Small ubiquitin-like modifier 3-modified proteome regulated by brain ischemia in transgenic mice – Stroke, 2014

  2. 🧬 Interactions of connexin 43 and aquaporin-4 in glioma-induced brain edema – Mol Med Rep, 2015

  3. 🧠 Neuron-specific SUMO knockdown worsens outcome after brain ischemia in mice – Neuroscience, 2017

  4. 🦴 Silencing Ubc9 suppresses osteosarcoma and enhances chemosensitivity via Connexin 43 SUMOylation – Int J Oncol, 2018

  5. ❤️ SERCA2a: a key protein in the calcium cycle of heart failure – Heart Fail Rev, 2019

  6. 💓 Zinc-induced SUMOylation of Drp1 protects heart from ischemia-reperfusion injury – Oxid Med Cell Longev, 2019

  7. 🧠 Genetic polymorphisms and transcription in intracranial aneurysm involving NOTCH3 – Aging (Albany NY), 2019

  8. 🧪 Saikosaponin-d inhibits hepatoma and enhances chemosensitivity via SENP5-dependent Gli1 SUMOylation – Front Pharmacol, 2019

  9. 🧬 Parkin and Nrf2 prevent apoptosis in endplate chondrocytes via mitophagy – Life Sci, 2019

  10. 🧫 MitoQ protects against disc degeneration by targeting mitochondrial dysfunction – Cell Prolif, 2020

🧾 Conclusion:

Dr. Xiaozhi Liu stands out as a highly qualified and deserving candidate for the Best Researcher Award. His blend of clinical neurosurgery, translational laboratory research, and molecular innovation, particularly in SUMOylation and neuroprotection, positions him at the forefront of modern biomedical science in China. With a leadership role in a major hospital, strong national research recognition, and a substantial academic footprint, he exemplifies excellence in research and mentorship.

Lingyan Zhou | Cell Death Pathway | Best Researcher Award

Published on by Cell Biologist

Dr. Lingyan Zhou | Cell Death Pathway | Best Researcher Award

Dr. Lingyan Zhou , Shandong Provincial Hospital Affiliated to Shandong First Medical University , China

Dr. Lingyan Zhou is a dedicated neuroscientist and clinician specializing in the pathogenesis of neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease. Currently serving in the Department of Neurology at Shandong Provincial Hospital affiliated with Shandong First Medical University, Dr. Zhou holds a doctorate and has made notable contributions to neurodegeneration research through high-impact publications and cutting-edge studies. Her work focuses on molecular mechanisms such as protein aggregation, homocysteinylation, and neuroprotection, with particular attention to α-synuclein and DJ-1. Dr. Zhou has co-authored more than 15 peer-reviewed articles in top-tier journals like Nature Communications, Science Advances, and Aging Cell, earning recognition for her insights into disease-modifying pathways. A researcher with a strong translational focus, she bridges the gap between bench and bedside, aiming to develop therapeutic strategies that can mitigate or reverse neurodegenerative processes. Her commitment to science and patient-centered research makes her a strong candidate for the Best Researcher Award.

Publication Profile:

Orcid

✅ Strengths for the Award:

  1. Strong Publication Record in High-Impact Journals
    Dr. Zhou has consistently published in top-tier journals such as Nature Communications, Science Advances, Aging Cell, and Movement Disorders, reflecting the significance and innovation of her work. Many of these are Q1 journals with high impact factors.

  2. Focused Research on Neurodegeneration
    Her core focus on the molecular basis of Alzheimer’s and Parkinson’s disease, especially novel mechanisms like N-homocysteinylation, STAT1-PARP1, and microRNA signaling, demonstrates depth and relevance to global health priorities.

  3. Translational Impact
    Her research bridges basic science and clinical application, particularly through studies on neuroprotection, early disease biomarkers, and potential therapeutic targets.

  4. Early Career Excellence
    Despite being in the early stages of her career, Dr. Zhou has already authored or co-authored over 17 peer-reviewed publications, many as first or corresponding author, which is exceptional at this stage.

  5. Multidisciplinary Collaborations
    Dr. Zhou’s collaborations with experts across genetics, immunology, bioinformatics, and neurology highlight her integrative approach to complex diseases.

  6. International Visibility
    Multiple articles are indexed in PubMed, Crossref, and DOIs, showing her research has international academic presence and reach.

⚠️ Areas for Improvement:

  1. Greater International Exposure
    While her publication record is strong, further participation in international neuroscience conferences, workshops, or global consortia would enhance visibility and foster leadership roles.

  2. Grant Leadership and Independent Funding
    As she progresses, securing independent research funding and leading grant-funded projects will further demonstrate research independence and strengthen her candidacy for top-tier awards.

  3. Mentorship and Teaching Roles
    Involvement in structured mentorship or supervision of Ph.D./postdoctoral researchers could be better highlighted to show contributions to research training and capacity building.

  4. Innovation Translation Pathway
    Filing patents or initiating translational collaborations with biotech/pharma could underline the practical applicability of her findings.

🎓 Education:

Dr. Lingyan Zhou received her doctorate from Wuhan University, one of China’s leading research institutions, between September 2020 and June 2023. During her Ph.D. training, she developed expertise in molecular neuroscience and translational medicine, with a specific focus on the pathological mechanisms underlying Parkinson’s and Alzheimer’s diseases. Her research explored cellular stress pathways, protein misfolding, and epigenetic regulation in neurodegeneration, leading to multiple first-author publications in high-impact journals. Her academic background provided a solid foundation in experimental techniques such as immunohistochemistry, gene expression analysis, and in vivo disease modeling. The interdisciplinary approach at Wuhan University enriched her understanding of both clinical neurology and basic neuroscience. This rigorous academic training has equipped Dr. Zhou with the analytical and research skills necessary for advancing innovation in neurodegenerative disease treatment.

🧪 Experience:

Since July 2023, Dr. Lingyan Zhou has been serving in the Department of Neurology at Shandong Provincial Hospital affiliated with Shandong First Medical University, where she engages in both clinical practice and translational neuroscience research. Prior to that, she completed her doctoral studies at Wuhan University, where she developed a deep interest in the role of homocysteine metabolism and genetic regulation in Parkinson’s disease. Over her career, she has collaborated with multidisciplinary teams to investigate molecular and cellular mechanisms of neurodegeneration and published extensively in internationally recognized journals. Her current position allows her to continue high-impact research while mentoring junior colleagues and participating in multi-center studies. Her combined experience in basic research, clinical neurology, and academic collaboration has established her as a key contributor in the field of neurodegenerative diseases, positioning her well for leadership roles and research recognition such as the Best Researcher Award.

🧠 Research Focus:

Dr. Lingyan Zhou’s research is centered on understanding the molecular and cellular mechanisms that drive neurodegenerative diseases, with an emphasis on Alzheimer’s and Parkinson’s disease. Her work has shed light on pathological protein modifications, such as N-homocysteinylation of α-synuclein and DJ-1, which contribute to protein aggregation and neurotoxicity. Additionally, she investigates the neuroprotective roles of vitamins, retinoic acid, and microRNAs in slowing disease progression. Dr. Zhou is also exploring how infectious diseases like SARS-CoV-2 may trigger or exacerbate neurological disorders, expanding the understanding of systemic factors in brain health. Her studies leverage both in vitro and in vivo models to unravel pathways involving STAT1, PARP1, and Notch signaling. By identifying potential therapeutic targets and biomarkers, her research aims to guide the development of novel treatment strategies that could improve outcomes for patients suffering from movement disorders and cognitive decline.

📚 Publications Top Notes:

  1. 🧪 N-homocysteinylation of alpha-synuclein promotes its aggregation and neurotoxicity – Aging Cell (2022)

  2. 🧠 Association of vitamin B2 intake with cognitive performance in older adults: a cross-sectional study – J Transl Med (2023)

  3. 🧬 Homocysteine and Parkinson’s disease – CNS Neurosci Ther (2023)

  4. 🧴 Retinoic Acid Prevents alpha-Synuclein Preformed Fibrils-Induced Toxicity via Inhibiting STAT1-PARP1 Signaling – Mol Neurobiol (2023)

  5. 🧫 N-homocysteinylation of DJ-1 promotes neurodegeneration in Parkinson’s disease – Aging Cell (2024)

  6. 🦠 SARS-CoV-2: Underestimated damage to nervous system – Travel Med Infect Dis (2020)

  7. 💊 Potential therapeutic drugs for ischemic stroke based on bioinformatics analysis – Int J Neurosci (2019)

  8. 🧬 PTPN22 Gene Polymorphisms and Stroke Susceptibility – Dis Markers (2019)

  9. 🧪 IL-18 Gene Polymorphisms and Risk of Ischemic Stroke: A Meta-analysis – Neuroreport (2019)

  10. 🚬 Aromatic hydrocarbon receptor links smoking and rheumatoid arthritis – Clin Exp Rheumatol (2020)

🧾 Conclusion:

Dr. Lingyan Zhou demonstrates an exceptional trajectory for a young neuroscience researcher. Her deep and original contributions to unraveling molecular mechanisms in neurodegeneration, particularly Parkinson’s and Alzheimer’s disease, make her highly deserving of recognition. The breadth and quality of her publication record—combined with her translational outlook—signal a rising star in neurodegenerative disease research.

Balbino Alarcón | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Balbino Alarcón | Cancer Cell Biology | Best Researcher Award

Prof. Dr. Balbino Alarcón , Consejo Superior de Investigaciones Científicas , Spain

Balbino Alarcón is a leading Spanish immunologist renowned for his contributions to T cell biology and immune signaling. Currently serving as Profesor de Investigación at the Consejo Superior de Investigaciones Científicas (CSIC), he has been affiliated with the Centro de Biología Molecular Severo Ochoa since 2002. His research has played a pivotal role in uncovering mechanisms of T cell receptor (TCR) signaling and immune system regulation. Dr. Alarcón holds a PhD in Biology from the Universidad Autónoma de Madrid, where he began shaping his scientific journey in the early 1980s. Over the decades, he has authored numerous impactful publications, many in top-tier journals, and holds several patents licensed to biotech companies. His work bridges fundamental immunology with translational applications in autoimmunity and cancer. With a keen focus on molecular signaling, his research continues to influence both basic science and therapeutic innovation in immunology.

Publication Profile:

Google Scholar

✅ Strengths for the Award:

  1. Outstanding Research Contributions:
    Dr. Alarcón has made seminal contributions to immunology, especially in T cell receptor (TCR) signaling, immune synapse formation, and immune cell communication. His work has appeared in top-tier journals like Cell, Immunity, Nature Communications, and Journal of Experimental Medicine.

  2. Impactful Publications & Citations:
    His research includes several highly cited papers (e.g., >500 citations), underlining the influence of his work on the broader scientific community.

  3. Translational Achievements:
    He holds multiple patents on immunomodulatory molecules (e.g., AX-024), which were licensed to biotech company Artax Biopharma, bridging basic science and clinical application.

  4. SARS-CoV-2 Research Leadership:
    He actively contributed to COVID-19 immunity research, developing flow cytometry-based antibody detection techniques and tracking longitudinal immune responses to infection and vaccination.

  5. Longevity and Commitment:
    Over 40 years of consistent research activity, with continuous affiliation to one of Spain’s most prestigious scientific institutions, CSIC.

  6. International Collaboration:
    He co-authored papers with leaders in immunology, showing global recognition and collaboration.

🛠️ Areas for Improvement:

  • Public Engagement & Visibility:
    Despite scientific acclaim, more visibility in public science communication, conference keynote roles, or leadership in global immunology consortia would further support his candidacy.

  • Mentorship Highlighting:
    While his academic stature suggests mentorship, documentation or awards for training young scientists could enhance his profile for broader awards recognizing holistic impact.

  • Innovation Metrics:
    Increased emphasis on clinical translation or successful product development from his patents could strengthen claims to innovation-driven recognitions.

🎓 Education:

Dr. Balbino Alarcón completed his undergraduate degree (Licenciado en Biología) in 1982 and his PhD in Biology with a specialization in Biochemistry in 1985, both from the Universidad Autónoma de Madrid, Spain. During his academic formation, he developed a deep interest in immunological signaling, particularly in how T cells communicate with their environment. His early education laid the foundation for a distinguished research career that has spanned more than three decades. His doctoral studies were focused on cellular and molecular immunology, equipping him with the tools to explore intricate signaling pathways. This robust educational background positioned him for leadership roles in immunological research, both nationally and internationally. Through rigorous academic training and continuous research contributions, Dr. Alarcón has become a key figure in advancing our understanding of T cell function and immune regulation.

👨‍🔬 Experience:

Dr. Balbino Alarcón has over 40 years of experience in immunological research, with a primary focus on T cell receptor (TCR) signaling and lymphocyte activation. Since July 27, 2002, he has held the position of Profesor de Investigación at the Consejo Superior de Investigaciones Científicas (CSIC), working at the Centro de Biología Molecular Severo Ochoa in Madrid, Spain. His academic and research career began with groundbreaking studies in T cell immunobiology, leading to discoveries such as the role of conformational changes in TCR activation. Dr. Alarcón has also been deeply involved in translational research, co-developing immunomodulatory drugs and securing patents that were licensed to Artax Biopharma. He regularly collaborates with leading immunologists and institutions worldwide, contributing to high-impact publications and international scientific reviews. His expertise and sustained contributions have made him a mentor and authority in molecular immunology and T cell biology.

🏅 Awards and Honors:

Dr. Balbino Alarcón’s distinguished career is highlighted by several prestigious awards and intellectual property recognitions. He co-developed two patented immunosuppressive strategies based on TCR signaling inhibition: one disrupting the TCR-Nck interaction and another involving chromene derivatives. Both patents were licensed to Artax Biopharma, showcasing the real-world therapeutic relevance of his research. He has authored highly cited publications, including foundational work published in Cell, Immunity, and Annual Review of Immunology, with citations in the hundreds. These contributions have not only advanced the field of immunology but also positioned Dr. Alarcón as a thought leader in immune signal transduction. He has been recognized nationally and internationally for his scientific achievements, serving as an editorial contributor and co-author of influential immunological reviews. His work continues to shape both academic and pharmaceutical research, making him a strong candidate for Best Researcher Awards.

🔬 Research Focus:

Dr. Alarcón’s research centers on the molecular mechanisms governing T cell receptor (TCR) activation and signal transduction. His work dissects how T cells recognize antigens and how intracellular signaling cascades translate these interactions into immune responses. A significant aspect of his research has involved understanding the conformational dynamics of the TCR/CD3 complex and how this affects T cell sensitivity and activation thresholds. He also explores the role of RRas2 in T and B cell function, including its relevance in lymphomagenesis and autoimmunity. Recently, he has contributed to understanding immune responses to SARS-CoV-2 and methods to detect neutralizing antibodies. His interdisciplinary approach integrates cell biology, molecular immunology, and translational research, linking fundamental science to clinical applications such as vaccine development and immunotherapy. By targeting TCR-associated pathways, Dr. Alarcón’s research opens new avenues in the treatment of immune-related diseases and cancer.

📚 Publications Top Notes:

  1. 🧫 RRas2 is required for germinal center formation to aid B cells during energetically demanding processes (Sci Signal, 2018)

  2. 🧪 A window of opportunity for cooperativity in the T Cell Receptor (Nat Commun, 2018)

  3. 🧬 Antigen phagocytosis by B cells is required for a potent humoral response (EMBO Rep, 2018)

  4. ⚙️ RRAS2 shapes the TCR repertoire by setting the threshold for negative selection (J Exp Med, 2019)

  5. 💊 Small molecule AX-024 targets T cell receptor signaling by disrupting CD3ε-Nck interaction (J Biol Chem, 2020)

  6. 🧪 Flow cytometry multiplexed method for the detection of Neutralizing human antibodies to SARS-CoV-2 (EMBO Mol Med, 2021)

  7. 🧬 Antigen presentation between T-cells drives Th17 polarization under limiting antigen (Cell Rep, 2021)

  8. 🧫 Detection of sustained humoral immune response (IgG + IgA) in SARS-CoV-2 infection (Sci Rep, 2021)

  9. 🧠 SFRP1 modulates astrocyte-to-microglia crosstalk in neuroinflammation (EMBO Rep, 2021)

  10. 💉 Longitudinal dynamics of SARS-CoV-2-specific immunity after infection or vaccination (PLoS Pathog, 2021)

🧾 Conclusion:

Dr. Balbino Alarcón is a highly deserving candidate for the Best Researcher Award. His pioneering studies in T cell signaling, impactful biomedical patents, and active role in immune response to infectious diseases demonstrate excellence in both basic and translational immunology. With decades of productive research, interdisciplinary collaboration, and consistent scientific leadership, he embodies the qualities celebrated by such an award.

Raphaël Rodriguez | Molecular Mechanisms Signaling | Best Researcher Award

Published on by Cell Biologist

Prof. Raphaël Rodriguez | Molecular Mechanisms Signaling | Best Researcher Award

Prof. Raphaël Rodriguez , CNRS, Institut Curie, France

Raphaël Rodriguez, born October 27, 1978, in Avignon, France, is a pioneering chemical biologist and Research Director at CNRS, Principal Investigator at Institut Curie, and holder of the Skłodowska-Curie Chair of Chemical Biology. A French citizen with two children, Lucía del Mar and Aramis, Rodriguez is renowned for bridging chemistry and biology to unlock the molecular secrets of cancer and inflammation. Trained in the UK under legendary scientists Sir J. E. Baldwin, Sir S. Balasubramanian, and Sir S. P. Jackson, he returned to France to launch groundbreaking research on ferroptosis and metal regulation in cell adaptation. His entrepreneurial and academic excellence earned him numerous accolades, including the National Order of Merit. With more than 130 publications and several successful biotech ventures, Rodriguez continues to shape the future of medical science with bioactive molecules like Ironomycin and Pyridostatin. He is an editorial board member, reviewer, teacher, and a public voice on science.

Publication Profile:

Google Scholar

✅ Strengths for the Award:

  1. Pioneering Scientific Impact:
    Dr. Rodriguez has contributed over 130 high-impact publications in top-tier journals like Nature, Science, JACS, Nature Chemistry, and Cell Metabolism. His work has helped define ferroptosis, a form of programmed cell death, and metal regulation in cancer—a game-changing area in molecular medicine.

  2. Innovation & Translation:
    He discovered and commercialized small molecules such as Pyridostatin, Ironomycin, and Supformin, directly impacting both science and therapeutics. His work bridges fundamental science and drug discovery.

  3. Leadership & Mentorship:
    From mentoring under renowned scientists to leading his own lab at Institut Curie, he has shaped France’s next generation of researchers in chemical biology.

  4. Recognition & Awards:
    His extensive list of prestigious awards, including the CNRS Silver Medal, Liliane Bettencourt Prize, and Knight of the National Order of Merit, reflect peer recognition on national and international levels.

  5. Entrepreneurship:
    As a co-founder of biotech companies (e.g., Adrestia Therapeutics, later acquired), he has demonstrated a rare capacity to translate discoveries into clinical and commercial value.

  6. Scientific Influence:
    Editorial board memberships and frequent invitations to over 160 major conferences show his reputation as a global thought leader in his field.

🔧 Areas for Improvement:

  1. Public Engagement Scaling:
    Although Dr. Rodriguez is active in media (radio, TV, print), expanding international science outreach (e.g., global science festivals, public lectures, social media presence) could help further democratize his scientific message.

  2. Clinical Translation:
    While several molecules from his lab are commercialized, more direct clinical trials or FDA approvals tied to his molecules would elevate his impact from bench to bedside.

  3. Collaborative Diversity:
    Encouraging more global South collaborations or mentorships could help broaden his lab’s international footprint and contribute to equitable science capacity building.

🎓 Education:

Raphaël Rodriguez’s academic journey is marked by elite training and impactful credentials across Europe. He earned his PhD in Chemistry (2002–2005) through a joint program between Marseille and Oxford. He then pursued postdoctoral research as a Senior Research Associate at Cambridge’s Department of Chemistry and Gurdon Institute (2005–2012), where he developed skills at the interface of chemistry and biology. In 2012, he obtained the prestigious Habilitation à Diriger des Recherches from the University of Paris-Saclay, enabling him to supervise PhD candidates and lead independent research. His rise through the academic ranks was rapid: he became a CNRS Group Leader in 2012, then Principal Investigator at Institut Curie in 2015. In 2017, he was promoted to Research Director (DR1) at CNRS. In 2020, he was awarded the Skłodowska-Curie Chair of Chemical Biology at Institut Curie. His interdisciplinary training under world-renowned mentors has uniquely positioned him at the forefront of chemical biology research.

💼 Experience:

Raphaël Rodriguez’s professional experience is a blend of high-level research, leadership, and innovation. He began his postdoctoral career at the University of Cambridge (2005–2012), working in the Department of Chemistry and the Gurdon Institute. In 2012, he became a CNRS Group Leader at ICSN, Gif-sur-Yvette, launching his independent research career. In 2015, he transitioned to Institut Curie as a Principal Investigator, where he deepened his focus on cancer and inflammation. His promotion to Research Director (DR1) at CNRS in 2017 reflects his impact and leadership. Awarded the Skłodowska-Curie Chair of Chemical Biology in 2020, Rodriguez oversees a productive lab that investigates ferroptosis, DNA structure, and metal ion regulation in disease. He is also an entrepreneur, co-founding Adrestia Therapeutics and OrbiThera. He teaches at PSL University, organizes international conferences, and contributes to editorial boards and scientific advisory boards worldwide, maintaining a strong presence in both academia and biotech.

🏆 Awards and Honors:

Raphaël Rodriguez has received an impressive array of honors, showcasing his impact on science and innovation. In 2024 alone, he won the CNRS Silver Medal and the Ligue Contre le Cancer Duquesne Prize. His earlier recognition includes the prestigious Liliane Bettencourt Prize for Life Sciences (2023), the Knight of the National Order of Merit (2022, presented by Nobel Laureate Jean-Marie Lehn), and the Klaus Grohe Prize (2022). He has also been awarded the Antoine Lacassagne Prize (Collège de France, 2019), the Sunrise Cancer Stem Cell Award (2019), the Charles Defforey–Institut de France Prize (2019), and the Tetrahedron Young Investigator Award (2019). Rodriguez is a Fellow of the Royal Society of Chemistry (2018) and won the Pierre Fabre Award for Therapeutic Innovation (2015). These accolades affirm his contributions across cancer research, chemical biology, and molecular therapeutics, as well as his success in translating science into societal benefit through entrepreneurship.

🔍 Research Focus:

Raphaël Rodriguez’s research lies at the cutting edge of chemical biology, with a focus on understanding how cells adapt to stress, particularly in the contexts of cancer and inflammation. His laboratory explores the role of metal ions—especially iron—as regulators of cellular plasticity and fate. Notably, his team discovered mechanisms underlying ferroptosis, a form of regulated cell death linked to iron metabolism, and how this can be exploited for anti-cancer therapies. He also investigates non-canonical DNA structures like G-quadruplexes, using small molecules to study and manipulate gene regulation. His lab has developed and commercialized several potent bioactive compounds, including Pyridostatin, Remodelin, Ironomycin, and Supformin, which are used both as research tools and potential therapeutics. Rodriguez combines molecular design, cell biology, and translational strategies, making his work a blueprint for chemical biology-driven precision medicine. He continues to raise significant research funding and actively collaborates across academia and biotech.

📚 Publications Top Notes:

  1. 🧬 Small-molecule–induced DNA damage identifies alternative DNA structures in human genes – Nature Chemical Biology

  2. ⚙️ Salinomycin kills cancer stem cells by sequestering iron in lysosomes – Nature Chemistry

  3. 🛡️ A novel small molecule that alters shelterin integrity and triggers a DNA-damage response at telomeres – JACS

  4. 🧫 Chemical inhibition of NAT10 corrects defects of laminopathic cells – Science

  5. 🧠 The transcription factor FOXM1 is a cellular target of the natural product thiostrepton – Nature Chemistry

  6. 🧪 Trisubstituted isoalloxazines as a new class of G-quadruplex binding ligands – JACS

  7. 🔥 PML-regulated mitochondrial metabolism enhances chemosensitivity in human ovarian cancers – Cell Metabolism

  8. 🔬 A single-molecule platform for investigation of G-quadruplex interactions with small-molecule ligands – Nature Chemistry

  9. 🧲 Small-molecule-mediated G-quadruplex isolation from human cells – Nature Chemistry

  10. 🧬 CD44 regulates epigenetic plasticity by mediating iron endocytosis – Nature Chemistry

  11. 🧷 Selective RNA vs DNA G-Quadruplex Targeting by In Situ Click Chemistry – Angewandte Chemie

  12. 🧬 G-Quadruplex-Binding Benzo[a]phenoxazines Down-Regulate c-KIT Expression in Gastric Carcinoma Cells – Journal of Medicinal Chemistry

🧾 Conclusion:

Dr. Raphaël Rodriguez exhibits exceptional merit and impact across the entire research ecosystem—fundamental science, innovation, mentorship, and commercialization. His trailblazing work in chemical biology, coupled with a record of scientific leadership and entrepreneurship, makes him highly deserving of the Best Researcher Award. His career reflects a rare blend of depth, vision, and cross-disciplinary innovation. Minor enhancements in global public engagement and clinical integration could further elevate his already stellar profile.

Mai Kadry | Biochemistry | Best Researcher Award

Published on by Cell Biologist

Assist. Prof. Dr. Mai Kadry | Biochemistry | Best Researcher Award

Assist. Prof. Dr. Mai Kadry  , NRC , Egypt

Dr. Mai Osman Mohamed Kadry is an Assistant Professor at the Therapeutic Chemistry Department of the National Research Centre in Egypt, specializing in molecular and biochemical research. With over two decades of experience, she has contributed significantly to the advancement of therapeutic chemistry. Dr. Kadry obtained her PhD in Biochemistry from Cairo University in 2016, focusing on oxidative injury mitigation through antioxidants. She has authored and co-authored multiple articles in prestigious journals. Her research is driven by a passion for finding therapeutic solutions to biochemical challenges, with a focus on molecular mechanisms and drug development.

Publication Profile:

Scopus

Strengths for the Award:

Dr. Mai Osman Mohamed Kadry has made significant contributions to the field of therapeutic chemistry, particularly in molecular and biochemical research. As an Assistant Professor at the National Research Centre (NRC), her dedication to scientific advancement is evident in her research on oxidative stress, drug-induced toxicity, and the potential of nanotechnology to mitigate such effects. Her work has been published in high-impact journals, showcasing her expertise in areas like cancer research, biochemistry, and drug development. Additionally, her comprehensive teaching experience in academic settings has strengthened her ability to impart knowledge to the next generation of researchers.

Areas for Improvement:

Although Dr. Kadry’s work is impressive, her research could further benefit from exploring more collaborative projects across different research centers and incorporating a broader range of interdisciplinary approaches. Engaging with cutting-edge technologies such as AI-driven drug discovery or multi-omics data analysis could significantly expand her impact on therapeutic chemistry.

Education:

Dr. Mai Kadry’s academic journey began with a Bachelor’s degree in Pharmaceutical Sciences from Ain Shams University, graduating with honors in 2003. She later pursued an MSc in Pharmaceutical Sciences with a focus on Biochemistry from Helwan University in 2008. Her doctoral research at Cairo University led to a PhD in Biochemistry in 2016, where she studied the amelioration of oxidative stress induced by titanium dioxide nanoparticles in mice. This educational foundation has equipped her with a robust understanding of biochemistry, molecular biology, and drug therapy.

Experience:

Dr. Mai Kadry has a distinguished career at the National Research Centre (NRC) in Egypt, starting as an Assistant Researcher in 2004 and advancing to Assistant Professor in 2021. Over the years, she has contributed to groundbreaking research in therapeutic chemistry, particularly in the area of oxidative stress and drug toxicity. Dr. Kadry has also taught pharmacognosy at the Faculty of Pharmacy, 6 October University, and served on committees focusing on academic development. Her extensive teaching and research experience positions her as a leader in her field.

Research Focus:

Dr. Mai Kadry’s research focuses on therapeutic chemistry, exploring the molecular mechanisms of drug-induced toxicity, oxidative stress, and potential protective treatments. Her work investigates the impact of nanomaterials like titanium dioxide and their effects on cellular pathways. She also studies the synergistic potential of natural compounds to mitigate damage from toxins, using advanced biochemical methods to evaluate their efficacy. Additionally, Dr. Kadry has a keen interest in cancer research, focusing on autophagy signaling and the development of novel drug formulations.

Publications Top Notes:

  • “Titanium nanostructure mitigating doxorubicin-induced testicular toxicity in rats via regulating major autophagy signaling pathways” 🧬💉
  • “Inflammatory mediators-induced DNA damage in liver and brain injury: Therapeutic approach of 5-Methoy-N-acetyltryptamine” 🧠💊
  • “Necroptosis and autophagy in cisplatinum-triggered nephrotoxicity: Novel insights regarding their prognostic and diagnostic potential” 💊🩺
  • “Resveratrol-based nano-formulations as an emerging therapeutic strategy for ovarian carcinoma” 🎗️💡
  • “miR-122-IGF-1R signaling allied through the dysregulated lncRNA MALAT-1 expression in gastric carcinoma” 🧬🦠
  • “Reciprocal crosslink among MeCP2/BDNF/CREB signaling pinpointed in autism spectrum disorder” 🧠🔬
  • “CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy” 🧬🧬
  • “Collaboration of Hprt/K-RAS/c-Myc mutation in the oncogenesis of T-lymphocytic leukemia” 🩸⚗️
  • “Thioctic acid shield against lipopolysaccharide depression and endoplasmic reticulum stress: GR7M/Homer/ATF6 signaling” 🧬🛡️
  • “Titanium dioxide nanostructure-loaded Adriamycin surmounts resistance in breast cancer therapy” 🧬🎗️

Conclusion:

Dr. Mai Osman Mohamed Kadry stands out as an exemplary researcher in her field. Her focus on therapeutic chemistry, particularly in relation to oxidative stress, toxicity, and nanotechnology, positions her as a promising candidate for the Researcher of the Year Award. Through her continued contributions and potential for further interdisciplinary collaboration, she will likely continue to make pivotal advancements in the field of molecular and biochemical research.

 

 

 

Chunli Ma | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Ms. Chunli Ma | Stem Cell Research | Best Researcher Award

Ms. Chunli Ma  , Shandong Provincial Hospital Affiliated to Shandong First Medical University , China

Chunli Ma is a Master’s student at Shandong Provincial Hospital Affiliated with Shandong First Medical University in China. With a strong background in Optometry and Vision Science, Ma has expanded into Ophthalmology for her graduate studies. She possesses a deep understanding of ocular disorders and the corresponding diagnostic and treatment protocols. She is passionate about cellular and molecular experimentation, specializing in animal models for scientific research. Her expertise extends to experimental techniques that offer innovative solutions for eye injury and healing. Chunli’s work aims to improve corneal repair, reduce scarring, and enhance treatment outcomes for ocular diseases through advanced therapeutic approaches, including stem cell therapy and specialized eye drops.

Publication Profile:

Orcid

Strengths for the Award:

Chunli Ma is a promising researcher with a strong foundation in both clinical ophthalmology and experimental techniques. Her academic background in Optometry and Vision Science, along with her specialized focus on Ophthalmology, positions her as an emerging leader in the field. Ma’s contributions to the understanding and treatment of corneal injuries, particularly her work on exosomes derived from adipose mesenchymal stem cells and antibacterial eyedrops, have significant therapeutic potential. The formulation of exosomes into eyedrops to aid in rapid corneal healing and prevent scarring, along with the development of multifunctional eyedrops for treating bacterial keratitis, showcases her innovative approach to solving complex clinical challenges. Her ability to translate laboratory research into potential clinical applications is commendable. Moreover, her publications in well-regarded journals and ongoing involvement in impactful research add to her eligibility for the Best Researcher Award.

Areas for Improvement:

While Chunli Ma’s work demonstrates great potential, there are areas where she could continue to develop. Expanding her research to a broader range of ocular conditions beyond corneal injury and keratitis could make her work even more influential across various ophthalmic fields. Additionally, seeking more collaborations with interdisciplinary teams, such as those focusing on the genetic and molecular mechanisms of ocular diseases, could provide deeper insights and enhance her ability to tackle more complex issues. Although she has made valuable contributions to scientific publications, continuing to increase the number and impact of her published papers, especially in top-tier journals, will further solidify her reputation in the scientific community. Gaining experience in patent applications and commercialization of her research could also help bridge the gap between laboratory findings and real-world clinical application.

Education:

Chunli Ma completed her undergraduate degree in Optometry and Vision Science, where she gained foundational knowledge in ocular health and vision correction. Building on this, she pursued a Master’s degree in Ophthalmology, which allowed her to specialize in clinical and experimental ophthalmic research. Her academic journey includes hands-on research in cell biology, molecular techniques, and experimental models to address common ocular disorders, particularly in corneal injury repair. Chunli’s academic training has not only refined her diagnostic skills but also equipped her with cutting-edge knowledge in treatment and therapeutic strategies. Her graduate work bridges practical clinical care with advanced research, focusing on cellular regeneration, stem cell treatments, and tissue healing in the eye. This robust academic background underpins her ongoing commitment to advancing ophthalmic medicine through innovative scientific inquiry and applied research in the field of corneal injury and wound healing.

Experience:

Chunli Ma’s academic journey has been bolstered by hands-on experience in both clinical ophthalmology and cellular research. Her work in experimental ophthalmology has focused on the use of adipose mesenchymal stem cells for corneal repair, creating new methodologies for promoting healing and reducing scarring. She has demonstrated expertise in animal model management and experimentation, gaining insights into complex biological processes affecting eye injuries. Ma has contributed to the development of novel treatments, including multifunctional eye drops for both bacterial keratitis and corneal trauma. Her research findings have important clinical implications, directly informing therapeutic strategies for ocular health. Additionally, Ma’s experience includes publishing scientific articles, with a growing portfolio in well-regarded journals. This combination of clinical knowledge, experimental research, and hands-on technique has allowed her to make valuable contributions to ophthalmic science, particularly in terms of innovative solutions for corneal injury and healing.

Research Focus:

Chunli Ma’s research focus is centered on the mechanistic modulation of corneal injury and wound healing. She investigates the potential of stem cell-derived exosomes in promoting the regeneration of corneal tissues, with a particular interest in their role in reducing scarring after trauma. Her work delves into advanced therapeutic applications, such as multifunctional eye drops containing composite antibacterial and healing properties for the treatment of Pseudomonas aeruginosa keratitis. By targeting the underlying molecular and cellular mechanisms of corneal repair, Ma aims to offer innovative solutions for treating corneal injuries and infections. Her research also explores the impact of wound size and location on the prognosis of penetrating ocular injuries, offering a more nuanced approach to patient care. Chunli’s focus on the development of cutting-edge materials and therapies for ophthalmic applications promises significant advances in clinical practice, particularly for patients with challenging corneal conditions.

Publications Top Notes:

  1. Exosomes derived from adipose mesenchymal stem cells promote corneal injury repair and inhibit the formation of scars by anti-apoptosis 📑🧬
  2. Wound size and location affect the prognosis of penetrating ocular injury 👁️‍🗨️🩹
  3. Potential role of ARG1 c.57G > A variant in Argininemia 🔬🧬

Conclusion:

Chunli Ma’s research reflects an excellent blend of clinical expertise and innovative scientific inquiry. Her work has already made notable contributions to improving the treatment of ocular injuries, particularly in corneal healing and bacterial keratitis. With a clear focus on translational research, she has demonstrated the potential for significant advancements in ophthalmic treatments. Given her ongoing dedication to advancing ophthalmology through novel therapeutic approaches, Chunli Ma is undoubtedly a strong candidate for the Best Researcher Award. With continued growth in her research, collaboration efforts, and scholarly output, she has the potential to make even greater strides in the field of ophthalmology and regenerative medicine.